ABSTRACT
It was discovered that during the first several months military service men have suppression of several indexes of immunity and a high level of morbidity by pyoderma. Was shown a high effectiveness of immunomodulatory agent Imunofan on correction of immunity status of servicemen and decrease of morbidity by pyoderma (more than on threefold): the effectiveness index is 3,25, the defense index is 69,2%. In addition, it was marked hepatitis- and stress-protect effect of the agent. It was made a conclusion about necessity of further examination of questions of correction of immunity status of military servicemen for the purpose of decrease of morbidity by infections, actual for studying units of the Armed Forces of RF.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Military Personnel , Oligopeptides/therapeutic use , Pyoderma/immunology , Pyoderma/prevention & control , Adjuvants, Immunologic/administration & dosage , Adolescent , Adult , Drug Administration Schedule , Humans , Immunity, Cellular/drug effects , Immunity, Humoral/drug effects , Immunity, Innate/drug effects , Military Personnel/education , Military Personnel/statistics & numerical data , Oligopeptides/administration & dosage , Pyoderma/blood , Pyoderma/epidemiology , Russia , Treatment Outcome , Young AdultSubject(s)
Military Hygiene , Occupational Diseases , Skin Diseases , Subcutaneous Tissue , Humans , Military Hygiene/organization & administration , Military Hygiene/standards , Military Hygiene/trends , Military Personnel , Occupational Diseases/epidemiology , Occupational Diseases/etiology , Occupational Diseases/prevention & control , Risk Factors , Russia , Seasons , Skin Diseases/epidemiology , Skin Diseases/etiology , Skin Diseases/prevention & controlABSTRACT
The evaluation of local peroxide status was studied in 42 patients with psoriasis depending on the disease stage in different age periods (from 18 to 67 years) with disease duration from 2 months to 20 years. It was established that the development of psoriatic process is accompanied with the marked changes in local peroxide status in the epidermis. It is manifested by the decrease in intensity of lipid free-and-radical oxidation. Decrease in the products of lipoperoxidation occurs in epidermis--both in the affected and intact areas in all investigated patients independently of the stage of psoriatic process. It is more expressed during the aggravation period. The minimal levels of the intermediators being studied are recorded in the psoriatic plaques.
